Physician profile
Kyle K Nelson
NPI 1316998180
$3,039.72
in general payments reported to CMS, 2019-2025
31 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $530 · 2021: $601 · 2022: $363 · 2023: $291 · 2024: $406 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.70 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $593.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $328.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $301.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $284.51 | 2019-2024 | Trelegy Ellipta, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.40 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $214.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $180.61 | 2021-2024 | |
| Allergan, INC. | $140.74 | 2019-2020 | |
| Astellas Pharma US INC | $93.02 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.59 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $69.05 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $57.13 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $46.73 | 2021-2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $44.20 | 2024-2025 | Voquezna |
| Amgen INC. | $38.92 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $34.23 | 2025 | Sapien 3 Ultra Resilia |
| Takeda Pharmaceuticals U.S.A., INC. | $28.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.21 | 2019-2021 | |
| Olympus America INC. | $25.08 | 2022 | |
| Exact Sciences Corporation | $20.68 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $20.29 | 2025 | Spectra Wavewriter |
| Eisai INC. | $19.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.60 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.47 | 2022 | |
| Shire North American Group INC | $17.34 | 2019 | |
| Dynavax Technologies Corporation | $17.20 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $14.87 | 2025 | Capvaxive, Gardasil 9 |
| Intra-Sana Laboratories | $13.56 | 2022 | |
| Horizon Therapeutics Plc | $13.48 | 2021 | |
| Esperion Therapeutics, INC. | $13.01 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.